Skip to main content
Top
Published in: Diabetologia 3/2004

01-03-2004 | Short Communication

The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and Objectives

Authors: S. A. Hills, B. Balkau, S. W. Coppack, J. M. Dekker, A. Mari, A. Natali, M. Walker, E. Ferrannini, Report prepared on behalf of the EGIR-RISC Study Group

Published in: Diabetologia | Issue 3/2004

Login to get access

Abstract

Aims/hypotheses

Insulin resistance is thought to be a key predictor for the development of Type 2 diabetes mellitus and cardiovascular disease (CVD), a leading cause of morbidity and premature mortality in Europe. Insulin resistance is influenced by both genetic and lifestyle factors (e.g. obesity and physical inactivity). The RISC (Relationship between Insulin Sensitivity and Cardiovascular disease) Study is using the infrastructure of an extended European collaborative research group to study insulin resistance and CVD risk in 1500 healthy people aged 30 to 60 years from 20 centres in 13 countries.

Methods

Baseline measurements of glucose tolerance and insulin sensitivity are made by the oral glucose tolerance test and the euglycaemic insulin clamp, respectively; carotid artery intima-medial thickness (by ultrasound), ankle/brachial pressure index and electrocardiography will enable evaluation of subclinical CVD at baseline and at follow-up. Classic CVD risk factors, as well as socioeconomic and lifestyle factors will be recorded at baseline; samples for measurement of biochemical and genetic markers will be collected and stored for future analyses. Investigations will be repeated after 3 and 10 years to evaluate the relationship between insulin resistance and the development of atherosclerosis as measured by carotid artery intima-media thickness. Development of Type 2 diabetes, dyslipidaemia, obesity, hypertension and cardiovascular events are additional endpoints.

Conclusions

This study will evaluate the importance of insulin resistance in the development of CVD and diabetes, and has implications for the development of prevention and treatment strategies.
Literature
1.
go back to reference Reaven GM (1988) Banting Lecture. Role of insulin resistance in human disease. Diabetes 37:1595–1607CrossRefPubMed Reaven GM (1988) Banting Lecture. Role of insulin resistance in human disease. Diabetes 37:1595–1607CrossRefPubMed
2.
go back to reference Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP (1992) Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41:715–722CrossRefPubMed Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP (1992) Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41:715–722CrossRefPubMed
3.
go back to reference Isomaa B, Almgren P, Tuomi T et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689CrossRefPubMed Isomaa B, Almgren P, Tuomi T et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689CrossRefPubMed
4.
go back to reference Bonora E, Formentini G, Calcaterra F et al. (2002) HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 25:1135–1141CrossRefPubMed Bonora E, Formentini G, Calcaterra F et al. (2002) HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 25:1135–1141CrossRefPubMed
5.
go back to reference Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, Howard BV, Strong Heart Study (2003) Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 26:861–867CrossRefPubMed Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, Howard BV, Strong Heart Study (2003) Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 26:861–867CrossRefPubMed
6.
go back to reference Laakso M (1993) How good a marker is insulin level for insulin resistance? Am J Epidemiol 137:959–965CrossRefPubMed Laakso M (1993) How good a marker is insulin level for insulin resistance? Am J Epidemiol 137:959–965CrossRefPubMed
7.
go back to reference Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE (2000) A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes 49:2094–2101CrossRefPubMed Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE (2000) A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes 49:2094–2101CrossRefPubMed
8.
9.
go back to reference Howard G, O’Leary DH, Zaccaro D et al. (1996) Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 93:1809–1817CrossRefPubMed Howard G, O’Leary DH, Zaccaro D et al. (1996) Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 93:1809–1817CrossRefPubMed
10.
go back to reference Ferrannini E, Vichi S, Beck-Nielsen H, Laakso M, Paolisso G, Smith U on behalf of EGIR (1996) Insulin action and age. Diabetes 45:947–953CrossRefPubMed Ferrannini E, Vichi S, Beck-Nielsen H, Laakso M, Paolisso G, Smith U on behalf of EGIR (1996) Insulin action and age. Diabetes 45:947–953CrossRefPubMed
11.
go back to reference Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G on behalf of EGIR (1997) Insulin resistance and hypersecretion in obesity. J Clin Invest 100:1166–1173CrossRefPubMedPubMedCentral Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G on behalf of EGIR (1997) Insulin resistance and hypersecretion in obesity. J Clin Invest 100:1166–1173CrossRefPubMedPubMedCentral
12.
go back to reference Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Jrvinen H on behalf of EGIR (1997) Insulin resistance, hyperinsulinemia, and blood pressure. Role of age and obesity. Hypertension 30:1144–1149CrossRefPubMed Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Jrvinen H on behalf of EGIR (1997) Insulin resistance, hyperinsulinemia, and blood pressure. Role of age and obesity. Hypertension 30:1144–1149CrossRefPubMed
13.
go back to reference Baldeweg SE, Golay A, Natali A, Balkau B, Del Prato S, Coppack SW on behalf of EGIR (2000) Insulin resistance, lipid and fatty acid concentration in 867 healthy Europeans. Eur J Clin Invest 30:45–52CrossRefPubMed Baldeweg SE, Golay A, Natali A, Balkau B, Del Prato S, Coppack SW on behalf of EGIR (2000) Insulin resistance, lipid and fatty acid concentration in 867 healthy Europeans. Eur J Clin Invest 30:45–52CrossRefPubMed
14.
go back to reference Vaag A, Lehtovirta M, Thye-Ronn P, Groop L (2001) Metabolic impact of a family history of type 2 diabetes. Results of a European multicentre study (EGIR). Diabetic Med 18:533–540CrossRefPubMed Vaag A, Lehtovirta M, Thye-Ronn P, Groop L (2001) Metabolic impact of a family history of type 2 diabetes. Results of a European multicentre study (EGIR). Diabetic Med 18:533–540CrossRefPubMed
15.
go back to reference Natali A, Toschi E, Camastra S, Gastaldelli A, Groop L, Ferrannini E, on behalf of EGIR (2000) Determinants of post-absorptive endogenous glucose output in non-diabetic subjects. Diabetologia 43:1266–1272CrossRefPubMed Natali A, Toschi E, Camastra S, Gastaldelli A, Groop L, Ferrannini E, on behalf of EGIR (2000) Determinants of post-absorptive endogenous glucose output in non-diabetic subjects. Diabetologia 43:1266–1272CrossRefPubMed
16.
go back to reference Ferrannini E, Camastra S, Coppack SW, Fliser D, Golay A, Mitrakou A on behalf of EGIR (1997) Insulin action and non-esterified fatty acids. Proc Nutrition Soc 56:753–761CrossRef Ferrannini E, Camastra S, Coppack SW, Fliser D, Golay A, Mitrakou A on behalf of EGIR (1997) Insulin action and non-esterified fatty acids. Proc Nutrition Soc 56:753–761CrossRef
17.
go back to reference Camastra S, Bonora E, Del Prato S, Rett K, Weck M, Ferrannini E, on behalf of EGIR (1999) Effect of obesity and insulin resistance on resting and glucose-induced thermogenesis in man. Int J Obes 23:1307–1313CrossRef Camastra S, Bonora E, Del Prato S, Rett K, Weck M, Ferrannini E, on behalf of EGIR (1999) Effect of obesity and insulin resistance on resting and glucose-induced thermogenesis in man. Int J Obes 23:1307–1313CrossRef
18.
go back to reference Rose GA, Blackburn H, Gillum RF, Prineas RJ (1982) Cardiovascular survey methods. World Health Organization, Geneva Rose GA, Blackburn H, Gillum RF, Prineas RJ (1982) Cardiovascular survey methods. World Health Organization, Geneva
19.
go back to reference Leng GC, Fowkes FG (1992) The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol 45:1101–1109CrossRefPubMed Leng GC, Fowkes FG (1992) The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol 45:1101–1109CrossRefPubMed
20.
go back to reference Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ (2001) A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 24:539–548CrossRefPubMed Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ (2001) A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 24:539–548CrossRefPubMed
21.
go back to reference Mari A, Tura A, Gastaldelli A, Ferrannini E (2002) Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes 51 [Suppl 1]:S221–S226 Mari A, Tura A, Gastaldelli A, Ferrannini E (2002) Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes 51 [Suppl 1]:S221–S226
22.
go back to reference Brage S, Brage N, Franks PW et al. (2004) Branched equation modeling of simultaneous accelerometry and heart rate monitoring improves estimate of directly measured physical activity energy expenditure. J Appl Physiol 96:343–351CrossRefPubMed Brage S, Brage N, Franks PW et al. (2004) Branched equation modeling of simultaneous accelerometry and heart rate monitoring improves estimate of directly measured physical activity energy expenditure. J Appl Physiol 96:343–351CrossRefPubMed
23.
go back to reference Craig CL, Marshall AL, Sjostrom M et al. (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35:1381–1395CrossRefPubMed Craig CL, Marshall AL, Sjostrom M et al. (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35:1381–1395CrossRefPubMed
24.
go back to reference Mercuri M, McPherson DD, Bassiouni H, Glagov S (1998) Non-invasive imaging of atherosclerosis. Kluwer, The Netherlands Mercuri M, McPherson DD, Bassiouni H, Glagov S (1998) Non-invasive imaging of atherosclerosis. Kluwer, The Netherlands
25.
go back to reference Mazzone AM, Urbani MP, Picano E et al. (1995) In vivo ultrasound parametric imaging of carotid atherosclerotic plaque by videodensitometric technique. Angiology 46:663–672CrossRefPubMed Mazzone AM, Urbani MP, Picano E et al. (1995) In vivo ultrasound parametric imaging of carotid atherosclerotic plaque by videodensitometric technique. Angiology 46:663–672CrossRefPubMed
Metadata
Title
The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and Objectives
Authors
S. A. Hills
B. Balkau
S. W. Coppack
J. M. Dekker
A. Mari
A. Natali
M. Walker
E. Ferrannini
Report prepared on behalf of the EGIR-RISC Study Group
Publication date
01-03-2004
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 3/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1335-5

Other articles of this Issue 3/2004

Diabetologia 3/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.